NCT06855212View on ClinicalTrials.gov

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cemiplimab

Given by IV infusion.

DRUG

Cetuximab

Given by IV infusion.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER